TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 2719903

Group type: EXPERIMENTAL
Intervention: Oral aqueous solution
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Controlled release oral tablet (MST-Continus)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Controlled release buccal tablet
Number of subjects: 6

Group type: COMPARATOR
Intervention: Intravenous morphine
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Oral morphine
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Buccal morphine
Number of subjects: 6
Study: 1099022

Group type: EXPERIMENTAL
Intervention: Methylphenidate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 29017022

Group type: EXPERIMENTAL
Intervention: Hypertrophic training (HYP I) for 10 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Maximum strength training (MS) for 10 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Power training (P) for 10 weeks following MS
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Maximum strength training (MS) followed by power training (P)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hypertrophic training (HYP II)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Maximum strength training (MS) and power training (P)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: RFD parameters
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Monitoring RFD
Number of subjects: 0
Study: 27569351

Group type: EXPERIMENTAL
Intervention: Naftopidil 75 mg for 8 weeks
Number of subjects: 31

Group type: COMPARATOR
Intervention: Tamsulosin 0.2 mg and Solifenacin 5 mg for 8 weeks
Number of subjects: 31
Study: 24844611

Group type: EXPERIMENTAL
Intervention: High-Ca group (600 mg of calcium per day)
Number of subjects: 220

Group type: COMPARATOR
Intervention: Low-Ca group (300 mg of calcium per day)
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Mid-Ca group (300 mg of calcium per day)
Number of subjects: 220
Study: 22349456

Group type: EXPERIMENTAL
Intervention: Peer-support intervention designed to improve diabetes self-care behaviors
Number of subjects: 424

Group type: COMPARATOR
Intervention: Multi-disciplinary diabetes education program
Number of subjects: 424
Study: 20185072

Group type: EXPERIMENTAL
Intervention: Pegged glenoid component
Number of subjects: 53

Group type: COMPARATOR
Intervention: Keeled glenoid component
Number of subjects: 53
Study: 19018337

Group type: EXPERIMENTAL
Intervention: Unsedated transnasal gastroscopy
Number of subjects: 20
Study: 15961933

Group type: EXPERIMENTAL
Intervention: SEDIsystem (automated analyzer for ESR measurement)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Westergren method (manual method for ESR measurement)
Number of subjects: 150
Study: 14559319

Group type: EXPERIMENTAL
Intervention: 200 microg daily of Se as selenomethionine (SeMet) for 4 weeks
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo for 4 weeks
Number of subjects: 22
Study: 10965636

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Systemic-behavioral family therapy (SBFT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nondirective supportive therapy (NST)
Number of subjects: 0
Study: 8783053

Group type: EXPERIMENTAL
Intervention: Experimental mouthrinse containing 0.4% zinc sulphate and 0.15% triclosan
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Experimental mouthrinse group 2
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control mouthrinse
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Experimental mouthrinse groups
Number of subjects: 0
Study: 1479631

Group type: EXPERIMENTAL
Intervention: Combined intervention addressing obsessive-compulsive symptoms and substance abuse
Number of subjects: 60

Group type: COMPARATOR
Intervention: Substance abuse treatment only
Number of subjects: 60

Group type: COMPARATOR
Intervention: Attention control group receiving treatment for substance abuse and training in progressive muscle relaxation
Number of subjects: 60
Study: 6367665

Group type: EXPERIMENTAL
Intervention: Prazosin hydrochloride (1 mg orally three times a day)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 30712461

Group type: EXPERIMENTAL
Intervention: Active rTMS
Number of subjects: 21

Group type: COMPARATOR
Intervention: Sham stimulation (Control)
Number of subjects: 21
Study: 29948524

Group type: EXPERIMENTAL
Intervention: Pit latrine sampling for Giardia lamblia
Number of subjects: 0

Group type: COMPARATOR
Intervention: Hospital submission samples for Giardia lamblia
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pit latrine sampling for Cryptosporidium spp.
Number of subjects: 0
Study: 27468708

Group type: EXPERIMENTAL
Intervention: L-AGE diet
Number of subjects: 138

Group type: COMPARATOR
Intervention: Reg-AGE diet
Number of subjects: 138
Study: 24456328

Group type: EXPERIMENTAL
Intervention: CERA (continuous erythropoietin receptor activator)
Number of subjects: 94
Study: 22581236

Group type: EXPERIMENTAL
Intervention: Active 2-mA tDCS
Number of subjects: 30

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 30
Study: 19717534

Group type: EXPERIMENTAL
Intervention: Exemestane
Number of subjects: 219

Group type: COMPARATOR
Intervention: Tamoxifen
Number of subjects: 219
Study: 17337164

Group type: EXPERIMENTAL
Intervention: Duloxetine treatment for 7-14 days
Number of subjects: 10
Study: 16255011

Group type: EXPERIMENTAL
Intervention: 5 mg/day prednisolone
Number of subjects: 192

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 192
Study: 12000111

Group type: EXPERIMENTAL
Intervention: Internet-based skin cancer triage intervention
Number of subjects: 46

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 46
Study: 10394821

Group type: EXPERIMENTAL
Intervention: Enteral feeding
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Immune‐enhancing diets
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Active components (arginine, glutamine, omega‐3 fats)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Parenteral feeding
Number of subjects: 0
Study: 7493437

Group type: EXPERIMENTAL
Intervention: Cholecystokinin-8 infusion
Number of subjects: 6

Group type: COMPARATOR
Intervention: Saline infusion
Number of subjects: 6
Study: 1801571

Group type: EXPERIMENTAL
Intervention: Red wine flavors with 20 prior exposures
Number of subjects: 34

Group type: COMPARATOR
Intervention: Red wine flavors with 5 or 0 prior exposures
Number of subjects: 34

Group type: COMPARATOR
Intervention: Sons of alcoholics
Number of subjects: 34
Study: 6638128

Group type: EXPERIMENTAL
Intervention: 0.5% timolol with 0.01% benzalkonium chloride
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 0.5% timolol without benzalkonium chloride
Number of subjects: 40

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 40
Study: 31394914

Group type: EXPERIMENTAL
Intervention: Oral appliance therapy
Number of subjects: 93
Study: 29936724

Group type: EXPERIMENTAL
Intervention: Good knowledge of HPV vaccination
Number of subjects: 280

Group type: EXPERIMENTAL
Intervention: Age of respondents
Number of subjects: 280

Group type: COMPARATOR
Intervention: Poor knowledge of HPV vaccination
Number of subjects: 280
Study: 26791031

Group type: EXPERIMENTAL
Intervention: 3-D planning-assisted implantation
Number of subjects: 56

Group type: COMPARATOR
Intervention: Freehand insertion of the acetabular cup (Control)
Number of subjects: 56
Study: 23836095

Group type: EXPERIMENTAL
Intervention: Psychological help to enhance self-confidence, motivation, and mood management
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Supportive general practice environment
Number of subjects: 16
Study: 21517955

Group type: EXPERIMENTAL
Intervention: Prandial + basal insulin
Number of subjects: 46

Group type: COMPARATOR
Intervention: Basal insulin
Number of subjects: 46
Study: 19236501

Group type: EXPERIMENTAL
Intervention: Neuroaid (4 capsules, 3 times daily for 3 months)
Number of subjects: 874

Group type: COMPARATOR
Intervention: Placebo (4 capsules, 3 times daily for 3 months)
Number of subjects: 874
Study: 16810765

Group type: EXPERIMENTAL
Intervention: Electric Knife (EK)
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Electro-Coagulation (EC)
Number of subjects: 220

Group type: COMPARATOR
Intervention: Control
Number of subjects: 220
Study: 12762431

Group type: EXPERIMENTAL
Intervention: Eradication treatment (ET group) with Lansoprazol 30 mg/day for three months
Number of subjects: 27

Group type: COMPARATOR
Intervention: Symptomatic treatment (ST group) with Lansoprazol 30 mg/day for three months
Number of subjects: 27
Study: 10690445

Group type: EXPERIMENTAL
Intervention: Progressive resistance exercise (PRE) for 52 weeks, three one hour sessions a week
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control group (normal lifestyle)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Dynamic leg strength
Number of subjects: 44
Study: 10175551

Group type: EXPERIMENTAL
Intervention: Breath-actuated inhaler (BAI)
Number of subjects: 301

Group type: COMPARATOR
Intervention: Manually operated metered dose inhaler (MDI)
Number of subjects: 301
Study: 8228122

Group type: EXPERIMENTAL
Intervention: i.v. imipenem/cilastatin
Number of subjects: 100

Group type: COMPARATOR
Intervention: Dextrose-saline (control)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Emergency sclerotherapy
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Elective sclerotherapy
Number of subjects: 100
Study: 3767127

Group type: EXPERIMENTAL
Intervention: Albuterol (4.0 mg)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Terbutaline (5.0 mg)
Number of subjects: 20
Study: 30583332

Group type: EXPERIMENTAL
Intervention: i-gelTM
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: AuraOnceTM
Number of subjects: 101
Study: 24673362

Group type: EXPERIMENTAL
Intervention: Adherence intervention
Number of subjects: 180

Group type: COMPARATOR
Intervention: Nonadherent pattern
Number of subjects: 180
Study: 25091820

Group type: EXPERIMENTAL
Intervention: Aspirin (160mg/day) plus citalopram (20mg/day)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo plus citalopram (20mg/day)
Number of subjects: 10
Study: 22384973

Group type: EXPERIMENTAL
Intervention: YINYI stent (polymer-free paclitaxel-eluting stent)
Number of subjects: 167

Group type: COMPARATOR
Intervention: EXCEL stent (biodegradable polymer-based rapamycin-eluting stent)
Number of subjects: 167
Study: 20167066

Group type: EXPERIMENTAL
Intervention: Non-symbolic magnitude comparison task
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Verbal counting knowledge and simple arithmetic tests
Number of subjects: 65
Study: 18663300

Group type: EXPERIMENTAL
Intervention: Fluoridated dentifrice (twice per day)
Number of subjects: 29
Study: 18083023

Group type: EXPERIMENTAL
Intervention: Fulvestrant 750mg
Number of subjects: 60

Group type: COMPARATOR
Intervention: Tamoxifen 20mg
Number of subjects: 60
Study: 15363566

Group type: EXPERIMENTAL
Intervention: Dutasteride 0.5mg daily (D/D group)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo followed by Dutasteride 0.5mg daily (P/D group)
Number of subjects: 0
Study: 11605561

Group type: EXPERIMENTAL
Intervention: Task instructions emphasizing position
Number of subjects: 0

Group type: COMPARATOR
Intervention: Task instructions emphasizing colour
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Stimuli similar to those used by van der Heijden et al.
Number of subjects: 0
Study: 9390608

Group type: EXPERIMENTAL
Intervention: Neostigmine 2.0 mg and glycopyrrolate 0.4 mg intravenously (Group A)
Number of subjects: 162

Group type: COMPARATOR
Intervention: No drugs to facilitate antagonism of blockade (Group B)
Number of subjects: 162
Study: 7808034

Group type: EXPERIMENTAL
Intervention: 13‐cis retinoic acid
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hydroxy phenyl retinamide
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Standard response criteria
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Response rates as low as 5%
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Survival
Number of subjects: 0
Study: 3662385

Group type: EXPERIMENTAL
Intervention: Labetalol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 30842038

Group type: EXPERIMENTAL
Intervention: nal-IRI + 5-FU/LV
Number of subjects: 417

Group type: COMPARATOR
Intervention: 5-FU/LV
Number of subjects: 417
Study: 30113876

Group type: EXPERIMENTAL
Intervention: 256-Hz tuning fork sensation groups (TFSG)
Number of subjects: 36
Study: 26874927

Group type: EXPERIMENTAL
Intervention: Pay-for-performance (P4P) intervention
Number of subjects: 6848
Study: 25277549

Group type: EXPERIMENTAL
Intervention: Endobronchial valve (EBV) therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Medical management (control)
Number of subjects: 0
Study: 22381771

Group type: EXPERIMENTAL
Intervention: TMZ-RT group (60 Gy radiotherapy with concurrent temozolomide treatment)
Number of subjects: 96

Group type: COMPARATOR
Intervention: VM-RT group (60 Gy radiotherapy with concurrent VM-26 plus Me-CCNU treatments)
Number of subjects: 96
Study: 20155520

Group type: EXPERIMENTAL
Intervention: Psychosocial intervention in dementia home care
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Multidisciplinary case management
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Respite care
Number of subjects: 0
Study: 17332104

Group type: EXPERIMENTAL
Intervention: Blinded outcome assessment
Number of subjects: 32

Group type: COMPARATOR
Intervention: Unblinded outcome assessment
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Blinded outcome assessment (dichotomous outcomes)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Unblinded outcome assessment (dichotomous outcomes)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Unblinded to blinded outcomes assessment ratio
Number of subjects: 32
Study: 16277142

Group type: EXPERIMENTAL
Intervention: Internet-based behavioral lifestyle modification program
Number of subjects: 57

Group type: COMPARATOR
Intervention: Internet-based health education program (control)
Number of subjects: 57
Study: 12443672

Group type: EXPERIMENTAL
Intervention: Oral killed cholera vaccine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Natural infections with enterotoxigenic Escherichia coli
Number of subjects: 0
Study: 10442154

Group type: EXPERIMENTAL
Intervention: Antioxidant supplement (20,000 IU beta-carotene, 400 IU vitamin E, 500 mg vitamin C, 100 micrograms selenium, 30 mg zinc)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Antioxidant supplement
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 8546287

Group type: EXPERIMENTAL
Intervention: Propofol infusion (total dose 860 mg, range 540‐1520 mg)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Isoflurane (median end‐expiratory concentration 0.6%, range 0.5‐0.8)
Number of subjects: 30
Study: 2692675

Group type: EXPERIMENTAL
Intervention: EMLA
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 820703

Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Indomethacin
Number of subjects: 35
Study: 30922964

Group type: EXPERIMENTAL
Intervention: DPP-4 inhibitors (DPP-4i)
Number of subjects: 0

Group type: COMPARATOR
Intervention: α-glucosidase inhibitor (acarbose)
Number of subjects: 0
Study: 27856001

Group type: EXPERIMENTAL
Intervention: Enteral high-fat polyunsaturated fatty acid (HF-PUFA) blend of fish oil and safflower oil
Number of subjects: 32

Group type: COMPARATOR
Intervention: Standard nutritional therapy (control)
Number of subjects: 32
Study: 25523240

Group type: EXPERIMENTAL
Intervention: Training towards painful faces
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Training away from painful stimuli (both faces and words)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Training on pain-related words
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Training on painful faces
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not explicitly defined)
Number of subjects: 0
Study: 24866715

Group type: EXPERIMENTAL
Intervention: Siblings' survival calendar (SSC)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Demographic and Health Surveys (DHS) questionnaire
Number of subjects: 0
Study: 22878126

Group type: EXPERIMENTAL
Intervention: Chemoradiation with capecitabine and cisplatin with or without cetuximab
Number of subjects: 50
Study: 20025685

Group type: EXPERIMENTAL
Intervention: Tacrolimus-based therapy
Number of subjects: 76

Group type: COMPARATOR
Intervention: Neoral cyclosporine-based therapy
Number of subjects: 76
Study: 17293709

Group type: EXPERIMENTAL
Intervention: quetiapine 600 mg/day
Number of subjects: 542

Group type: EXPERIMENTAL
Intervention: quetiapine 300 mg/day
Number of subjects: 542

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 542
Study: 15365065

Group type: EXPERIMENTAL
Intervention: Goserelin alone
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Goserelin and tamoxifen
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Tamoxifen alone
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Goserelin alone (1 year after cessation)
Number of subjects: 89
Study: 15264726

Group type: EXPERIMENTAL
Intervention: Ketamine 0.5 mg x kg(‐1) pre‐induction bolus followed by intravenous infusion of ketamine 0.5 mg x kg(‐1) x h(‐1) for 72 hours
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo (normal saline) as pre‐induction bolus followed by normal saline infusion for 72 hours
Number of subjects: 45
Study: 11713926

Group type: EXPERIMENTAL
Intervention: Sildenafil 50 mg
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 9407701

Group type: EXPERIMENTAL
Intervention: Zopiclone (7.5 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Diazepam (10 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 8428407

Group type: EXPERIMENTAL
Intervention: Urinary red cell morphology assessment by Observer 1 using phase-contrast microscopy
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Urinary red cell morphology assessment by Observer 2 using phase-contrast microscopy and Nomarski differential interference microscopy
Number of subjects: 62

Group type: COMPARATOR
Intervention: Comparison of Nomarski differential interference microscopy to phase-contrast microscopy
Number of subjects: 62
Study: 2890398

Group type: EXPERIMENTAL
Intervention: Artificial surfactant (ALEC)
Number of subjects: 328

Group type: COMPARATOR
Intervention: 1 ml saline (control)
Number of subjects: 328
Study: 31903494

Group type: EXPERIMENTAL
Intervention: BTI + Airman's Guide to Remaining Tobacco Free (AG)
Number of subjects: 2999

Group type: EXPERIMENTAL
Intervention: Airman's Guide to Remaining Tobacco Free (AG)
Number of subjects: 2999

Group type: COMPARATOR
Intervention: Standard smoking cessation intervention
Number of subjects: 2999
Study: 29668302

Group type: EXPERIMENTAL
Intervention: Upfront neck dissection (UFND)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Hypopharyngeal cancer and carcinoma of unknown primary
Number of subjects: 63

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 63
Study: 27229707

Group type: COMPARATOR
Intervention: IVB 1.25 mg
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: IVB 1.25 mg with STA 40 mg
Number of subjects: 45
Study: 26271061

Group type: EXPERIMENTAL
Intervention: Balloon-expandable valve
Number of subjects: 241

Group type: COMPARATOR
Intervention: Self-expandable valve
Number of subjects: 241
Study: 24111757

Group type: EXPERIMENTAL
Intervention: Intensive insulin therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Strict glycemic control
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intensive insulin therapy in critically ill patients
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study: 20855136

Group type: EXPERIMENTAL
Intervention: 30 ml of a fat emulsion (Calogen(®)) 3 times daily, providing 420 kcal
Number of subjects: 71

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 71
Study: 18332475

Group type: EXPERIMENTAL
Intervention: Letrozole (LET)
Number of subjects: 2383

Group type: COMPARATOR
Intervention: Placebo (PLAC)
Number of subjects: 2383
Study: 16580960

Group type: EXPERIMENTAL
Intervention: SPECT‐35%
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Planar RNA
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: SPECT‐QBS
Number of subjects: 10
Study: 12664054

Group type: EXPERIMENTAL
Intervention: Blood cardioplegia
Number of subjects: 14

Group type: COMPARATOR
Intervention: Crystalloid cardioplegia
Number of subjects: 14
Study: 10858989

Group type: EXPERIMENTAL
Intervention: IgE antibody titers to ovalbumin
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Concentration of pepsin-treated ovomucoid for 50% RAST inhibition
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Concentration of chymotrypsin-treated ovomucoid for 50% RAST inhibition
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Concentration of trypsin-treated ovomucoid for 50% RAST inhibition
Number of subjects: 21
Study: 8790077

Group type: EXPERIMENTAL
Intervention: Warfarin therapy
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Aspirin therapy
Number of subjects: 83

Group type: COMPARATOR
Intervention: Mild stroke
Number of subjects: 83

Group type: COMPARATOR
Intervention: Moderate stroke
Number of subjects: 83

Group type: COMPARATOR
Intervention: Major stroke
Number of subjects: 83
Study: 1592884

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 30 micrograms/kg oral GHRP
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 100 micrograms/kg oral GHRP
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 300 micrograms/kg oral GHRP
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 1 microgram/kg iv GHRP
Number of subjects: 10
Study: 6205052

Group type: EXPERIMENTAL
Intervention: 4 per cent chlorhexidine-detergent solution
Number of subjects: 3602

Group type: EXPERIMENTAL
Intervention: Routine cord care with 4 per cent chlorhexidine-detergent solution
Number of subjects: 3602
Study: 31376949

Group type: EXPERIMENTAL
Intervention: SURPAS
Number of subjects: 1006

Group type: COMPARATOR
Intervention: ACS-SRC
Number of subjects: 1006
Study: 30311348

Group type: EXPERIMENTAL
Intervention: Long-chain omega-3 polyunsaturated fatty acid (LCn3PUFA) intake
Number of subjects: 351
Study: 28196620

Group type: EXPERIMENTAL
Intervention: In-person education
Number of subjects: 514

Group type: EXPERIMENTAL
Intervention: Online education
Number of subjects: 514
Study: 25543127

Group type: EXPERIMENTAL
Intervention: Brief Intervention (BI)
Number of subjects: 304

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 304
Study: 24576788

Group type: EXPERIMENTAL
Intervention: Diabetic patients with diabetic cardiomyopathy
Number of subjects: 2042

Group type: COMPARATOR
Intervention: Diabetic patients
Number of subjects: 2042